Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Peptides ; 39: 152-6, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23201312

RESUMO

Phasic pain demonstrates significant diurnal variation in rats. Angiotensin II modulates pain transmission and the diurnal variation in nociception in several rodent pain models. The participation of AT2 receptors in the diurnal regulation of nociception is not yet elucidated. In the present study we investigated the effects of selective peptide AT2 agonist CGP 42112A and the nonpeptide AT2 receptor antagonist PD 123319 on the nociception, motor coordination and arterial blood pressure. Male Wistar 12 weeks old rats were used. CGP 42112A was injected at single doses of 1 and 5 µg/rat intracerebroventricularly (ICV) and infused chronically ICV at a dose of 12 µg/rat/day during 14 days by osmotic minipumps. PD123319 was injected at single doses of 1 and 5 µg/rat, ICV and chronically subcutaneously at a dose of 10 mg/kg/day/14 days. Nociception was assessed by an analgesimeter, arterial blood pressure (ABP) was measured by tail cuff method, and motor coordination by Rota-rod method. Single doses of CGP 42112A (1 and 5 µg/rat) provoked a short lasting antinociception. Unlike acute injection, chronic CGP 42112A infusion increased nociception at the beginning and the end of light phase thus attenuating the diurnal variations observed in the controls. Moreover, it produced an increase of ABP and improved motor coordination. Both acute (1 µg/rat) and chronic PD 123319 treatment resulted in a decrease of pain threshold and chronic treatment attenuated its diurnal fluctuation. Our data support a role for Ang II type 2 receptors in the control of diurnal variations of nociception in rats.


Assuntos
Bloqueadores do Receptor Tipo 2 de Angiotensina II/farmacologia , Imidazóis/farmacologia , Atividade Motora/efeitos dos fármacos , Nociceptividade/efeitos dos fármacos , Oligopeptídeos/farmacologia , Piridinas/farmacologia , Receptor Tipo 2 de Angiotensina/fisiologia , Bloqueadores do Receptor Tipo 2 de Angiotensina II/administração & dosagem , Animais , Pressão Sanguínea/efeitos dos fármacos , Ritmo Circadiano/efeitos dos fármacos , Relação Dose-Resposta a Droga , Imidazóis/administração & dosagem , Infusões Intraventriculares , Infusões Subcutâneas , Masculino , Oligopeptídeos/administração & dosagem , Piridinas/administração & dosagem , Ratos , Ratos Wistar , Receptor Tipo 2 de Angiotensina/agonistas , Teste de Desempenho do Rota-Rod
2.
Methods Find Exp Clin Pharmacol ; 32(9): 663-8, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21225017

RESUMO

Angiotensin (AT) II plays a key role in the regulation of blood pressure and water-salt balance and modulates nociception. Peptides based on AT influence central functions through the activation of AT1, AT2 or AT4 receptors. The aim of this study was to elucidate the role of AT1 receptors in diurnal variation in nociception in spontaneously hypertensive rats (SHR). Male Wistar rats (16 weeks old) and SHR were caged individually and exposed to light from 08:00 to 20:00 h. The tail cuff method for noninvasive measurement of arterial blood pressure (ABP), paw pressure test for the determination of pain threshold and rotarod test to study motor coordination were used. Chronic treatment was administered to the SHR with the AT1 receptor antagonist losartan (10 mg/kg/day, s.c.) for 14 days. Spontaneously hypertensive rats showed lower pain threshold and smaller day-night variations of nociception as compared to Wistar rats. Chronic losartan decreased the ABP and produced an inverted diurnal pattern of nociception in SHR, increasing the pain threshold at 03:00 h. Neither strain differences nor changes in motor coordination after losartan treatment were observed in SHR. Our results suggest that SHR have disturbances in diurnal variation in nociception and that the AT1 receptor plays a role in the regulation of the circadian rhythm of mechanical pain threshold in SHR.


Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Ritmo Circadiano , Limiar da Dor , Receptor Tipo 1 de Angiotensina/metabolismo , Animais , Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Losartan/farmacologia , Masculino , Ratos , Ratos Endogâmicos SHR , Ratos Wistar , Receptor Tipo 1 de Angiotensina/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...